Comparison · NCT01369212-sae
Tenofovir vs Peginterferon-alfa 2a and Tenofovir: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tenofovir vs Peginterferon-alfa 2a and Tenofovir: serious adverse events. Trial comparisons, record NCT01369212-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01369212-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.108 | 0.0613 | 0.183 | wilson | |
| Risk in group 2 | 0.0707 | 0.0347 | 0.139 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0371 | -0.0454 | 0.12 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.53 | 0.616 | 3.78 | log | |
| Odds ratio, group 1 over group 2 | 1.59 | 0.59 | 4.28 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Tenofovir than on Peginterferon-alfa 2a and Tenofovir | 26.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tenofovir | Tenofovir 192 weeks~Tenofovir: 300 mg daily for 192 weeks (4 years) | 11 | 102 | EG000 |
| Group 2 | Peginterferon-alfa 2a and Tenofovir | A combination of peginterferon-alfa 2a plus tenofovir for 24 weeks and then tenofovir only for 168 weeks~Peginterferon-alfa 2a and tenofovir: A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years). | 7 | 99 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 240 weeks
Source ClinicalTrials.gov
Trial
- Title
- Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B
- NCT number
- NCT01369212
- Phases
- PHASE3
- Conditions
- Hepatitis B
- Interventions
- Tenofovir, Peginterferon-alfa 2a and tenofovir
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Results first posted
- 2022-10-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01369212?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01369212-sae